BIOREN (Predictive BIOmarkers in Metastatic RENal Cancer) - A Translational Study on Immunotherapy for Metastatic Renal Cancer


Condition: Renal Cancer Metastatic

Study Type: Observational

Clinical Trials Identifier NCT 8-digits: NCT03628859

Sponsor: Centre Leon Berard

Phase:

Eligibility:

  • Age: minimum 18 Years maximum N/A
  • Gender: All

Inclusion Criteria:

  • Age ≥ 18 years-old.
  • Histology proven locally advanced (unresectable) or metastatic clear cell renal cell carcinoma (mccRCC).
  • Starting 2nd or 3rd line of treatment with nivolumab, everolimus, axitinib or cabozantinib as per summaries of product characteristics (SmPC) or 1st line treatment with sunitinib or pazopanib or receiving 2nd or 3rd line of treatment with nivolumab
  • Signed informed consent.

Exclusion Criteria:

  • Psychological, familial, sociological, geographical conditions that would limit compliance with study protocol requirements.
  • Pregnant or breastfeeding woman

View trial on ClinicalTrials.gov


email news signup